Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of ($0.01), $0.01 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $13.9 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.